NeuroSense Therapeutics Ltd.
NRSNWNasdaq
$0.10
0.0%Jul 17 close · end-of-day
Price
1Y↓ -84.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.5M
Enterprise Value
$2.4M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-301.4%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.1M
Free Cash Flow (TTM)
-$7.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
713.1%
ROIC
—
Debt / Equity
—
Net Cash
$166,000.00
Return 1Y
-87.6%
Company profile
NeuroSense Therapeutics Ltd. focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis.
- CEO
- Alon Ben-Noon
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Website
- neurosense-tx.com
Management & directors
- Ben-Noon AlonChief Executive Officer
- Eisenberg OrChief Financial Officer
- Binder HagitGeneral Manager
- Russek-Blum NivaChief Technology Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$3.0M | -$10.6M | -$12.0M | -$9.9M | -$11.1M |
| Net income | -$3.2M | -$10.5M | -$10.1M | -$10.2M | -$11.1M |
| Diluted EPS | -$0.52 | -$0.91 | -$0.74 | -$0.54 | -$0.44 |
| Operating cash flow | -$1.5M | -$7.6M | -$8.4M | -$10.1M | -$7.7M |
| Free cash flow | -$1.6M | -$7.7M | -$8.4M | -$10.1M | -$7.7M |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
No quarterly data.
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | Eisenberg Or· Chief Financial Officer | Buy | 250,000 | $0.80 | $200,000.00 | filing |
| 2026-06-16 | Ben-Noon Alon· Chief Executive Officer | Buy | 250,000 | $0.80 | $200,000.00 | filing |
| 2026-03-26 | Eisenberg Or· Chief Financial Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-03-26 | Russek-Blum Niva· Chief Technology Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-03-26 | Binder Hagit· General Manager | Award | 200,000 | $0.00 | $0.00 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.